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INTRODUCTION
Chronic hepatitis C virus (HCV)b
infection is a major public health problem,
affecting over 2.7 million individuals in
the U.S. and over 170 million worldwide
[1, 2]. In the United States, HCV infection
is the most common cause ofchronic liver
disease, accounts for 8,000 to 10,000
deaths annually, and is the leading indica-
tion for liver transplantation [3]. Since the
initial discovery of HCV virus as the
causative agent of non-A, non-B (NANB)
hepatitis by Choo and colleagues in 1989
[4], significant advances have been made
in our understanding of its epidemiology,
pathogenesis, diagnosis, and therapy.
Increased understanding ofthe natural his-
tory of chronic infection will be essential
in any effort to further elucidate patho-
genetic mechanisms, predict clinical out-
comes, and identify those patients for
whom treatment is beneficial.
Acute infection with HCV virus is
usually asymptomatic, and therefore infre-
quently diagnosed during this earlyperiod.
Although up to one-third of patients may
develop mild flu-like symptoms or jaun-
dice, fulminant liver failure is very rare
[5]. Despite vigorous humoral and cell-
mediated immune responses by the host,
approximately 85 percent of patients fail
to achieve spontaneous recovery and thus
develop chronic infection, defined as a
positive HCV antibody and RNA at six
months. Chronic infection is typically
characterized by a prolonged asympto-
matic period, but will eventually lead to
chronic hepatitis, cirrhosis, and hepatocel-
lular carcinoma in 70 percent, 20 percent,
and 4 percent of cases, respectively [6].
Mechanisms for HCV persistence remain
unclear, but may involve viral mutation
during replication, persistence in extrahep-
atic tissues, or formation of quasispecies
that escape host immune response [7-8].
The natural history of HCV infection
has been difficult to study. Accurate deter-
mination requires a well-defined time of
disease onset and frequent, prospective
monitoring of clinico-pathologic out-
comes over the course ofinfection without
therapeutic intervention, ideally with a
matched control group for comparison.
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This has been limited by several factors: 1)
the time ofinfection onset or acute hepati-
tis is rarely identified; 2) chronic infection
is usually asymptomatic; 3) the develop-
ment ofmeasurable endpoints may require
several decades; 4) highly variable fre-
quency and timing of liver biopsies may
delay diagnosis ofcirrhosis until clinically
evident; and 5) many patients with HCV
infection have been exposed to antiviral
therapy. Nevertheless, a number of studies
conducted in the past ten years have con-
tributed important information about clini-
cal outcomes in chronic hepatitis C infec-
tion. Approaches used to study natural his-
tory have included prospective studies that
follow patients forward from time of dis-
ease onset (i.e., post-transfusion hepatitis),
retrospective studies that evaluate patients
with established clinical outcomes of
HCV infection, and nonconcurrent
prospective studies that follow cohorts
with historically defined times of disease
onset (i.e., recognized outbreaks of acute
hepatitis).
RETROSPECTIVE STUDIES
Current literature from retrospective
studies predicts that approximately 20 per-
cent of patients with chronic hepatitis C
will develop cirrhosis by twenty years of
infection [9], in whom a subset will
progress to decompensated hepatic failure
and hepatoma. Four retrospective studies
have investigated the rate of development
ofclinical outcomes in patients with estab-
lished chronic hepatitis, by tracing the
chronic disease back to an estimated time
of disease onset [10-13]. While obviating
the need for a prolonged follow-up period,
these studies are limited by inherent uncer-
tainties in time of disease onset, a system-
atic exclusion of infected patients who
never seek medical attention due to spon-
taneous recovery or lack ofsymptoms, and
a disproportionate inclusion of patients
with particularly severe disease.
In 1990, Kiyosawa and colleagues
[10] described their results of a retrospec-
tive analysis of 231 patients with chronic
NANB hepatitis, in whom liver-related
complications were identified (96 patients
with chronic hepatitis, 81 patients with cir-
rhosis,and 29 patients with HCC). The
authors hypothesized that reliable infor-
mation on duration of infection could be
obtained only from those patients with an
accurate time ofdisease onset (i.e., history
of transfusion). Within each complication
group, patients with a history of transfu-
sion were identified andpoints ofinfection
determined. In this highly selected group
of patients with advanced disease, the
mean time interval between transfusion
and cirrhosis was approximately 21 years
(Table 1). Their observation provided the
earliest evidence that progression to seri-
ous clinical outcomes was a gradual
process that occurred over decades.
Tong and colleagues [11] corroborat-
ed these findings in their study of 213
patients with transfusion-related chronic
HCV infection, who were referred to their
tertiary care center because of: 1) alanine
aminotransferase (ALT) abnormalities; 2)
established liver disease; or 3) liver mass.
Liver biopsies were performed in 101 of
these patients, in whom alarmingly high
rates of complications occurred. Based on
the time of transfusion, intervals from
onset ofinfection to liver-related outcomes
were calculated (Table 1). A smaller group
of patients (131) in this study were fol-
lowed for an additional 3.9 years (mean),
during which seven more patients (5.3 per-
cent) developed HCC and twenty patients
(15.3 percent) died from liver-related com-
plications. These impressive numbers
clearly demonstrated the potential for life-
threatening outcomes in chronic HCV
infection, but likely grossly overestimated
its frequency due to severe referral bias.
Yano and colleagues [12] evaluated
the rate ofhistologic disease progression in
a cohort of 80 patients with HCV-relatedLim: Review ofhepatitis C 231
Table 1. Rate of progression of chronic HCV infection in retrospective studies.
Mean interval (years) between
transfusion and development
of disease
Author Country No. of patients Chronic hepatitis Cirrhosis HCC
Kiyosawa [10] Japan 231 10.0 ± 11.3 21.2 ± 9.6 29.0 ± 13.2
Tong [11] USA 213 13.7 ± 10.9 20.6 ± 10.1 28.3 ± 11.5
chronic liver disease (out of 2,000 eligible
participants) who underwent repeated liver
biopsies (mean 3.9) over a period of 2 to
26 years. Using a standardized system of
histopathology scoring for inflammation
and fibrosis, the authors were the first to
observe that the rate ofprogression to cir-
rhosis was accelerated in patients whose
initial biopsies demonstrated high grades
of necroinflammatory activity and evi-
dence of hepatic fibrosis. Several years
later, Gordon and colleagues [13] exam-
ined the relationship between route of
infection and clinical outcome in a group
of 627 nonalcoholic patients with chronic
HCV infection. Biopsy-demonstrated cir-
rhosis was found in 118 of215 patients (55
percent) with transfusion-related infection,
in contrast to only 40 of 195 patients (21
percent) who transmitted infection through
other parenteral routes. HCC also devel-
oped more commonly in the group with a
history of transfusion (4 percent versus 1
percent). The authors' findings suggested
that the risk of progressive liver failure in
hepatitis C infection may correlate with
mode of infection, and not duration of
infection alone.
PROSPECTIVE STUDIES
Five studies have followed patients
prospectively from the time of disease
onset to histologically defined outcomes
[14-18], all in the setting of transfusion-
associated NANB hepatitis. As expected,
the inclusion of a wider spectrum of both
healthy and symptomatic patients has
resulted in numbers suggesting a lower
rate of progression to end-stage liver dis-
ease (Table 2). These authors demonstrate
that the development of complications is
highly variable, but appears to be benign
in most patients during the first decade of
infection. These studies are limited, how-
ever, by the absence ofcontrols, the intro-
Table 2. Prospective long-term outcomes in patients with transfusion-associated
NANB hepatitis.
Mean
No. of follow-up Cirrhosis
Author Country patients (years) (Percent)
Hopf [14] Germany 86 8.0 24.0
DiBisceglie [15] USA 65 9.7 12.3
Tremolada [16] Italy 135 7.6 15.6
Koretz [17] USA 80 14.0 6.3
Mattson [18] Sweden 61 13.0 8.0232 Lim: Review ofhepatitis C
duction of disease-modifying treatments,
and short surveillance duration (range 7.6
to 14.0 years) that is clearly inadequate to
capture the full range of hepatitis C-relat-
ed complications.
The study boasting the longest dura-
tion of follow-up, conducted by Koretz
and colleagues [17], illustrates these limi-
tations well. Following documented acute
transfusion-associated NANB hepatitis in
90 patients, 80 were followed for approxi-
mately 16 years following transmission, in
whom 55 patients (69 percent) developed
chronic hepatitis C infection. Only eight
patients in this cohortprospectively under-
went liver biopsy, of whom three demon-
strated cirrhosis. An additional two
patients were reported to have documented
cirrhosis on earlier biopsies. Thus despite
a reassuring figure of6.3 percent cirrhosis
at a mean of 14.0 years, the absence of
more biopsy data prevents one from reach-
ing broader conclusions regarding long-
term outcomes. Notably, decompensated
liverdisease was estimated to be present in
19 percent of all patients in this cohort,
reflecting the true possibility of under-
diagnosis.
Several investigators have studied the
progression of disease beginning in
patients who already have established
chronic hepatitis. Poynard and colleagues
[19] have long described the course of
chronic hepatitis C infection in terms of
progression from chronic inflammation to
fibrosis to cirrhosis. Fibrosis stage and dis-
ease activity, as measured by standardized
histologic criteria (i.e., METAVIR scoring
system), may serve as valuable surrogate
markers for disease progression. In this
study, liverbiopsies of2,235 patients were
obtained from three large population-
based study groups, and reviewed singly
or in paired samples. Defining fibrosis
progression as a ratio between fibrosis
stage (in METAVIR units) and estimated
duration ofinfection (in years), the authors
reported a median rate offibrosis progres-
sion of0.133 fibrosis units per year, which
is independently increased by advanced
age (greater than 40 years old at time of
infection), daily alcohol consumption
(greater than 50 g/day), and male sex.
They further concluded that the median
estimated interval between infection and
cirrhosis is 30 years, ranging between 13
years (in male alcoholics over age 40) and
42 years (in non-drinking females infected
before age 40). This distribution suggests
the presence of at least three populations:
1) "rapid fibrosers" (progress to cirrhosis
in 5 to 10 years), 2) "intermediate
fibrosers" (cirrhosis in 11 to 30 years), and
3) "slow fibrosers" (cirrhosis in greater
than 30 years or not at all).
NONCONCURRENT PROSPECTIVE
STUDIES
During the past five years, the scien-
tific community has witnessed an explo-
sion of studies that identified for prospec-
tive evaluation a historically defined
cohort of patients with a clearly recog-
nized point ofinfection, usually in the set-
ting ofan acute outbreak ofNANB ortype
C hepatitis (Table 3) [20-27]. In nearly all
cases, the rate of progression to cirrhosis
at twenty or more years is significantly
less than suggested by retrospective study
literature. This supports the growing
notion among practicing hepatologists that
the natural history of chronic hepatitis C
infection is heterogeneous, and likely
more benign that previously believed.
Kenny-Walsh and the Irish
Hepatology Research Group [20]
described a long-term follow-up study of
704 women who received HCV-contami-
nated anti-D immune globulin in 1977,
and were found tobe anti-HCV positive 17
years later in 1994. Liver function tests
were normal in 45 percent of women. Of
363 women who underwent liver biopsies,
the vast majority demonstrated mild or
moderate necroinflammatory changes (93Lim: Review ofhepatitis C 233
Table 3. Nonconcurrent prospective outcomes in patients with historically defined
points of infection.
Mean
No. of follow-up Cirrhosis Year
Author Country patients (years) (Percent) Published
Kenny-Walsh [20] Ireland 376 17 2.0 1999
Wright [21] USA 568 23 15.0 1998
Muller [22] Germany 152 15 0.0 1996
Seeff [23] USA 17 50 0.06 2000
Gronbaek [24] Denmark 178 23 9.0 1999
Wiese [25] Germany 917 20 0.4 2000
Rodger [26] Australia 238 25 8.0 2000
Vogt [27] Germany 458 20 0.002 1999
percent) and portal or periportal fibrosis
was seen in 34 percent of patients.
Notably, however, fibrosis was absent in
nearly one-half of patients (49 percent)
and cirrhosis was found in only 2 percent
of patients. Muller [22] reported nearly
identical results in 152 German women
who received contaminated Rh immune
globulin, noting that not a single patient
demonstrated cirrhosis at 15 years of fol-
low-up. Similarly encouraging results
were reported by Wiese and colleagues
[25] from their evaluation of 917 East
German women who transmitted HCV
infection from contaminated immune
globulin. Nearly 85 percent of these
patients remained anti-HCV positive at 20
years, only 55 percent remained HCV
RNA positive, and cirrhosis was detected
in only four patients (0.4 percent), two of
whom were co-infected with hepatitis B
virus.
The surprisingly benign clinical out-
come observed in these patients may
reflect, in part, a very low-risk population
of young, otherwise healthy, non-drinking
women. It is uncertain if similar results
would be found in other populations. Yet
similar results were reported in long-term
follow-up studies of stored sera from
healthy young American military recruits
[23] and follow-up of healthy young
German adults with prior transfusion-
associated hepatitis [27], suggesting that
hepatitis C infection is likely associated
with few, if any long-term complications
in low-risk individuals.
More recently, Thomas and col-
leagues [28] prospectively evaluated the
incidence and predictors ofviral clearance
and advanced liver disease in a communi-
ty-based cohort of 919 patients who
acquired HCV infection in the context of
injection drug use. The authors recognized
that injection drug use accounts for 60 per-
cent of all new cases in the U.S. [29], and
that prior studies did not adequately evalu-
ate clinical outcomes in this population,
focusing instead on older transfusion-
infected patients with multiple co-mor-
bidities, or young, healthy immune globu-
lin recipients. The authors found that after
a median of 13.7 years ofdrug use and 8.8
years of follow-up, viral clearance
occurred more frequently in nonblacks
(OR 5.15) and that the risk for clinically
evident end-stage liver disease was higher
in patients who were over 38 years old
(OR 3.67) or drank >260g alcohol/week
(OR 3.60). Of210 patients who underwent
liver biopsy, only two (1 percent) demon-
strated cirrhosis. Drawing conclusions
from this study are limited by its use of a
proxy time of infection (onset of infection234 Lim: Review ofhepatitis C
defined as first reported injection drug
use), an inadequate duration of follow-up
to observe clinical end-points, and the use
of clinical definitions for end-stage liver
disease, clearly a less sensitive marker that
biopsy in detecting cirrhosis.
FACTORSTHAT MAY PROMOTE
DISEASE PROGRESSION
From the available literature of the
past three years, it is clear that cirrhosis
and its life-threatening complications are
not inevitable in all patients with hepatitis
C infection. Many viral, environmental,
and host factors may dramatically affect
the likelihood of promoting disease pro-
gression. Age at time of infection, male
gender, alcohol consumption, HIV co-
infection, low CD4 count, and HBV co-
infection have been clearly demonstrated
to accelerate fibrosis progression rate.
Viral factors such as viral load (RNA),
genotype, and quasispecies formation
have not been shown to be associated with
fibrosis progression.
The effect of alcohol on fibrosis
acceleration in patients with HCV infec-
tion is substantial even in moderate
amounts; abstinence should be encouraged
in most patients. Excessive amounts
greater than 40 g/day in women and 60
g/day in men dramatically and indepen-
dently increase the risk of cirrhosis [30-
31]. The mechanism remains unclear, but
may involve altered host immune response
to viral infection. Advanced age increases
fibrosis progression significantly through
heightened vulnerability to oxidative
stress and diminished immune capacity.
Statistical modeling has demonstrated that
the probability of disease progression in
men aged 61 to 70 was 300 times greater
than for men aged between 21 to 40, high-
lighting its important place clinical deci-
sion-making [32]. Females have been
found to have a ten-fold decreased pro-
gression rate than men at all ages, possible
related to estrogen-mediated modulation
offibrogenesis [33].
Co-infection with HIV is associated
with accelerated fibrosis progression, par-
ticularly in those patients with low CD4
counts (<200 cells/ul) or concurrently
drink alcohol [34]. Both of these risk fac-
tors accelerated the median expected time
to cirrhosis to 16 years from 36 years in
controls.
Co-infection with hepatitis B infec-
tion accelerates fibrosis and increases the
risk ofcirrhosis complicated by hepatocel-
lularcarcinoma [35]. Hepatitis A co-infec-
tion is usually self-contained but may
increase the risk for developing fulminant
hepatitis and hepatic failure [36].
Vaccination against hepatitis A and B
should be performed routinely inprevious-
ly unimmunized patients.
Although helpful in predicting
response to interferon-based therapy,
hepatitis C RNA and genotype do not cor-
relate with progression of disease [37-38]
The formation ofdistinct but closely relat-
ed viral mutants (quasispecies) within
individual patients was- previously
believed to be unrelated to severity of
HCV-related liver disease. However, a
recent investigation by Farci and col-
leagues suggests that examination of the
genetic diversity of the virus during the
first four months of infection may predict
whether HCV infection will become
chronic or resolve spontaneously [8]. The
authors detected a marked increase in the
genetic diversity of the hypervariable
region 1 (HVR1) of the virus in patients
with hepatitis that proved to be progres-
sive. Conversely, patients whose infection
eventually resolved demonstrated a
decrease in genetic diversity of HVR1, as
manifested by the mean number of non-
synonymous nucleotide substitutions per
week. This raises the possibility that dif-
ferent modes of HCV transmission may
result in critical differences in quasi-
species generation and genetic diversity,Lim: Review ofhepatitis C 235
thereby resulting in disparate clinical out-
comes.
CONCLUSIONS
Chronic HCV infection remains a
critical public health priority. Future mor-
bidity, mortality, and cost resulting from
hepatitis C-related care is expected to be
astronomical, with a predicted 165,900
deaths from chronic liver disease, 27,200
deaths from hepatocellular carcinoma, and
$10.7 billion in direct medical expendi-
tures between 2010-2019 [39]. Based on
current literature, we can safely predict
that most patients with hepatitis C infec-
tion will develop chronic hepatitis, and
that many ofthese patients will progress at
variable rates towardcirrhosis andits com-
plications. In midst of rapidly advancing
therapies [40] and prospects of exciting
new research animal models [41], our
facility in helping patients determine their
individual risks for disease progression
and suitability for treatment will be essen-
tial.
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